Tuesday, March 19

9:00 a.m.–12:00 p.m.

The Presidential Plenary Session features the AAN's premier lecture awards for clinically relevant research and a presentation by a leading lecturer. Top researchers speak on some of the most significant findings in neurology 2013.

Moderator: Lisa M. DeAngelis, MD, FAAN
Chair, AAN Science Committee and Scientific Program Subcommittee

Presidential Lecture

Bruce Sigsbee, MD, FAAN, President AAN
Penn Bay Physician and Associates, Rockport, ME
Special Invited Lecturer: Jerome B. Posner, MD, FAAN
Memorial Sloan–Kettering Cancer Center, New York, NY

H. Houston Merritt Lecture

M. Marsel Mesulam, MD, FAAN
Northwestern University Feinberg School of Medicine, Chicago, IL
Title: Primary Progressive Aphasia and the Language Network

Robert Wartenberg Lecture

Salvatore Di Mauro, MD
Columbia University Medical Center, New York, NY
Title: Mitochondrial Encephalomyopathies: 50 Years On

Tuesday, March 19

5:15 p.m.–6:15 p.m.

Members of the AAN Science Committee and AAN Scientific Program Subcommittee will note important and interesting abstracts presented at subspecialty meetings leading up to the Annual Meeting that are not on the program but should be heard by a wide audience at the Annual Meeting.

Moderator: Jose Merino, MD, MPhil
Member, Science Committtee

Rare and Common Genetic Risk Factors for Alzheimer's Disease

Alison Goate, D.Phil
Washington University School of Medicine, St. Louis, MO

Fungal Meningitis Outbreak: 2012

David B Clifford, MD, FAAN
Washington University School of Medicine, St. Louis, MO

Synthetic Tau Fibrils Mediate Transmission of Neurofibrillary Tangles in a Transgenic Mouse Model of Alzheimer's – like Tauopathy

John Q Trojanowski, MD, PhD
University of Pennsylvania, Philadelphia, PA

Effects of Cranial Radiation on Stem Cell Memory

Michelle Monje, MD, PhD
Stanford University, Stanford, CA

Wednesday, March 20

9:00 a.m.–12:00 p.m.

Highlights issues most critical to practicing neurologists, including abstracts related to new therapeutic developments, clinical applications of basic and translational research, and innovative technical developments Commentary and discussion select presentations.

Moderator: Lisa M. DeAngelis, MD, FAAN
Chair, AAN Science Committee and Scientific Program Subcommittee

Radiologically Isolated Syndrome (RIS): 5–Year Risk for an Initial Clinical Event from a Multinational Cohort

Darin Okuda, MD
Barrow Neurological Institute, Phoenix, AZ




Discussant: David H Miller, MBChB, MD, FRCP
Institute of Neurology, London, United Kingdom

Medical Management with mTOR Inhibitors vs. Surgical Resection: Comparison of Clinical Outcomes for Subependymal Giant Cell Astrocytoma (SEGA) in Tuberous Sclerosis Complex (TSC)

Susanne Yoon
Cincinnati Children's Hospital Medical Center, Cincinnati, OH




Discussant: David Viskochil, MD, PhD
University of Utah, Salt Lake City, UT

Clinicopathologic Correlations in 172 Cases of REM Sleep Behavior Disorder ± a Coexisting Neurologic Disorder

Bradley Boeve, MD
Mayo Clinic, Rochester, MN




Discussant: Ronald Postuma, MD
Montreal General Hospital, Montreal, QC, Canada

Brain Tumor Classification in Drug Development and Clinical Trials

Ingo K Mellinghoff, MD
Memorial Sloan–Kettering Cancer Center, New York, NY

Chronic Traumatic Encephalopathy

Daniel Perl, MD
Uniformed Services University of the Health Sciences, Bethesda, MD

Functional Plasticity in MS

Maria Assunta Rocca, MD
Ospedale San Raffaele, Milan, Italy

Thursday, March 21

9:00 a.m.–11:00 a.m.

Focuses on translational research related to important clinical issues. Four physician scientists outline their recent research findings, along with clinical implications.

Moderator: Natalia Sana Rost, MD
Vice–Chair, AAN Science Committee

Samuel F. Berkovic, MD, FACP
Epilepsy Research Center, Heidelberg, Australia
Epilepsy Genetics: Impact at the Clinic 2013

Roger Y. Tsien, PhD
University of California, San Diego
Howard Hughes Medical Institute
Building Molecules to Image Neuroinflammatory Disease Processes

Merit E. Cudkowicz, MD, MSc
Massachusetts General Hospital
Charlestown, MA
ALS Pathways to Treatments

Laura Fratiglioni, MD, PhD
Karolinksa Institute Aging Research Center
Stockholm, Sweden
Alzheimer's Disease in an Aging World

Thursday, March 21

4:00 p.m.–6:00 p.m.

The program features experts discussing the most current and controversial issues in neuroscience It is set up as a debate format in which two speakers argue a side of a single topic, followed by a rebuttal Each round concludes with a question and answer period.

Moderators: Joseph Jankovic, MD, FAAN & Walter A. Rocca, MD, MPH

Should Intra–arterial Therapy Be Used as Standard Treatment of Acute Stroke?

Pro: Raul G Nogueira, MD
Emory University, Atlanta, GA

Con: Pooja Khatri, MD
University of Cincinnati, Bethesda, MD

Should Levodopa Be Initiated at the Time of Diagnosis?

Pro: Stephen G Reich, MD, FAAN
University of Maryland Hospital, Baltimore, MD

Con: C Warren Olanow, MD, FAAN
Mt. Sinai Medical Center, New York, NY

Do Currently Applied Stem Cell Treatments Have Any Validity in the Treatment of Neurologic Disorders?

Pro: Lawrence Goldstein, PhD
University of California, San Diego, San Diego, CA

Con: Arnold R Kriegstein, MD, PhD
University of California, San Francisco, CA

Is the Evidence Sufficient to Give Vitamin D to Everybody in the General Population to Prevent Multiple Sclerosis?

Pro: Alberto Ascherio, MD, PhD
Harvard School of Public Health, Boston, MA

Con: George C Ebers, MD
University of Oxford, Oxford, United Kingdom

Friday, March 22

12:00 p.m.–1:30 p.m.

This midday session covers important clinical topics that affect patient care identified from other society meetings. Lecturers will present the latest updates within several clinical trials conducted over the last year. An open panel discussion concludes the session.

Moderator: Lisa M. DeAngelis, MD, FAAN
Chair, AAN Science Committee and Scientific Program Subcommittee

THE MS–STAT TRIAL: High Dose Simvastatin Slows Brain Atrophy and Delays Disability in Secondary Progressive Multiple Sclerosis: A Phase II Placebo-Controlled Trial

Jeremy Chataway, MD
Queen Square Multiple Sclerosis Centre, London, United Kingdom

Interventional Management of Stroke–3 Trial

Joseph P Broderick, MD, FAAN
University of Cincinnati, Cincinnati, OH

Phase III Trial of Bevacizumab Added to Standard Radiotherapy and Temozolomide for Newly Diagnosed Glioblastoma: Final Progression-Free Survival and Preliminary Overall Survival Results from AVAglio

Timothy Cloughesy, MD
University of California, Los Angeles, CA

Safety and Tolerability of Dexpramipexole for the Treatment of ALS: Results from the Randomized, Double–Blind, Placebo–Controlled Trial, EMPOWER

Leonard Van den Berg, MD
University Medical Center Utrecht, Utrecht, Netherlands

Efficacy of Dexpramipexole in Amyotrophic Lateral Sclerosis: Data from the Phase III EMPOWER Trial

Merit E Cudkowicz, MD, MSC
Massachusetts General Hospital, Charlestown, MA

Efficacy and Safety of Intravenous Solanezumab in Patients with Mild to Moderate Alzheimer Disease: Results of Two Phase 3 Studies

Ann Hake, MD
Lilly Corporate Center, Indianapolis, IN

Friday, March 22

5:15 p.m.–7:15 p.m.

This plenary session will feature six speakers, each focusing on the latest developments of interest to the clinician that have occurred within the last year in a specific subspecialty topic.

Moderator: Lisa M. DeAngelis, MD, FAAN
Chair, AAN Science Committee and Scientific Program Subcommittee

Stroke

Costantino Iadecola, MD
Weill Cornell Medical College, New York, NY

Neuro–ophthalmology

Nancy J Newman, MD, FAAN
Emory University School of Medicine, Atlanta, GA

ALS

Michael G Benatar, MBChB, DPhil, FAAN
University of Miami, Miami, FL

Epilepsy

Daniel H Lowenstein, MD
University of California, San Francisco, CA

Alzheimer's Disease

Eric Reiman, MD
Banner Health System, Phoenix, AZ

Multiple Sclerosis

Michael K Racke, MD
Ohio State University Medical Center, Columbus, OH

These programs are offered in partnership with the American Society of Neurorehabilitation, Society for Behavioral and Cognitive Neurology, the AAN Neural Repair and Rehabilitation Section, and the AAN Behavioral Neurology Section.

Friday, March 22, 2013
8:00 a.m.–12:00 p.m.
7HC.001: Neurorehabilitation Enhancement Techniques
Director: Randolph Marshall, MD, FAAN

1:00 p.m.–5:00 p.m.
IN11: Brain Stimulation: Clinical and Neuroscience Implications
Coordinators: Anjan Chatterjee, MD and H. Branch Coslett, MD

These programs are offered in partnership with the Child Neurology Society and the AAN Child Neurology Section.

Sunday, March 17, 2013
8:00 a.m.–12:00 p.m.
IN1: Pediatric Neuromuscular Diseases
Coordinators: Basil Darras, MD and Katherine Mathews, MD

2:00 p.m.–6:00 p.m.
2HC.006: Leukodystrophies
Director: Adeline Vanderver, MD

These programs are offered in partnership with the American Epilepsy Society and the AAN Epilepsy Section.

Friday, March 22, 2013
8:00 a.m.–12:00 p.m.
IN9: Inflammation in Epilepsy
Coordinators: Tallie Z. Baram, MD and Jacqueline French, MD

1:00 p.m.–5:00 p.m.
7HC.010: Epilepsy Co-Morbidities
Director: William Theodore, MD, FAAN

These programs are offered in partnership with the Society for Nuclear Medicine and Molecular Imaging and the AAN Geriatric Neurology Section.

Monday, March 18, 2013
8:00 a.m.–12:00 p.m.
IN3: Alzheimer's Biomarkers in Clinical Practice
Coordinators: Douglas Galasko, MD and Gil Rabinovici, MD

2:00 p.m.–6:00 p.m.
3HC.008: Amyloid Imaging: Are Neurologists Ready for the Paradigm Shift?
Director: Norman Foster, MD, FAAN

These programs are offered in partnership with the Movement Disorder Society and the AAN Movement Disorders Section.

Sunday, March 17, 2013
9:00 a.m.–1:00 p.m.
2HC.001: Clues to Synuclein Spread in Parkinson's Disease
Director: Kathleen Shannon, MD

2:00 p.m.–6:00 p.m
IN2: New Insights into Molecular Mechanisms in Parkinson's Disease
Coordinators: William Dauer, MD and Ming Guo, MD, PhD

These programs are offered in partnership with the North American Neuro-ophthalmology Society and the AAN Neuro-ophthalmology Section.

Monday, March 18, 2013
9:00 a.m.–1:00 p.m.
3HC.001: The Visual and Ocular Motor Systems in Neurodegenerative and Genetic Disease
Director: David Zee, MD, FAAN

2:00 p.m.–6:00 p.m.
IN4: Assessing Neurological Disease via the Visual and Ocular Motor Systems
Coordinators: Gregory Van Stavern, MD and Ari Green, MD